Relations between circulating microRNAs and atrial fibrillation: Data from the Framingham Offspring Study

Heart Rhythm

Volumn 11, Issue 4, 2014, Pages 663-669

  McManus, David D ^a,b   Lin, Honghuang ^a,c   Tanriverdi, Kahraman ^a,b   Quercio, Michael ^b   Yin, Xiaoyan ^a   Larson, Martin G ^a,d,e   Ellinor, Patrick T ^f   Levy, Daniel ^a,g   Freedman, Jane E ^a,b   Benjamin, Emelia J ^c,e  

^a FRAMINGHAM HEART STUDY   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Boston University   (United States)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Atrial fibrillation; Circulation; Epidemiology; microRNA; Risk factors

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; MICRORNA; MICRORNA 127 4B; MICRORNA 134; MICRORNA 150 5P; MICRORNA 151A 3P; MICRORNA 152; MICRORNA 182 5P; MICRORNA 193A 5P; MICRORNA 196B 5P; MICRORNA 200C 3P; MICRORNA 221 3P; MICRORNA 28 5P; MICRORNA 29B 2 5P; MICRORNA 31 3P; MICRORNA 328; MICRORNA 331 3P; MICRORNA 339 5P; MICRORNA 375; MICRORNA 720; MICRORNA 99B 5P; UNCLASSIFIED DRUG; MICRORNA 1274B;

AGED; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; HEART ATRIUM FIBRILLATION; HIGH THROUGHPUT SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BLOOD; GENETICS; LONGITUDINAL STUDY; ATRIAL FIBRILLATION; DIABETES MELLITUS; DISEASE ASSESSMENT; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REFRACTORY PERIOD; OBSERVATIONAL STUDY; PROGENY; PROSPECTIVE STUDY; RISK ASSESSMENT; RNA ISOLATION;

AGED; ATRIAL FIBRILLATION; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MICRORNAS;

EID: 84896986437     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2014.01.018     Document Type: Article

References (27)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (atria) study. JAMA 2001;285:2370-2375. (Pubitemid 32424106)
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-125. (Pubitemid 44420743)
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke 1991;22:983-988.
4. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003;107:2920-2925. (Pubitemid 36736633)
5. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-844.
6. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the united states. Value Health 2006;9:348-356. (Pubitemid 44337788)
7. Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from a National Heart, Lung, and Blood Institute workshop. Circulation 2009;119:606-618.
8. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature 2011;469:336-342.
9. Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G, Diwan A, Nerbonne JM, Dorn GW 2nd. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 2010;106:166-175.
10. Luo X, Pan Z, Shan H, Xiao J, et al. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest 2013;123:1939-1951.
11. Cardin S, Guasch E, Luo X, Naud P, Le Quang K, Shi Y, Tardif JC, Comtois P, Nattel S. Role for microRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ Arrhythm Electrophysiol 2012;5:1027-1035.
12. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008;105:13027-13032.
13. van Rooij E, Olson EN. Searching for miR-acles in cardiac fibrosis. Circ Res 2009;104:138-140.
14. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006;103:18255-18260. (Pubitemid 44871645)
15. Liu Z, Zhou C, Liu Y, Wang S, Ye P, Miao X, Xia J. The expression levels of plasma micoRNAs in atrial fibrillation patients. PLoS One 2012;7:e44906.
16. Schnabel RB, Larson MG, Yamamoto JF, et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation 2010;121:200-207.
17. Jang JS, Simon VA, Feddersen RM, Rakhshan F, Schultz DA, Zschunke MA, Lingle WL, Kolbert CP, Jen J. Quantitative miRNA expression analysis using fluidigm microfluidics dynamic arrays. BMC Genomics 2011;12:144.
18. Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 2012;44:670-675.
19. Alonso A, Krijthe BP, Aspelund T, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF Consortium. J Am Heart Assoc 2013;2:e000102.
20. http://www.Targetscan.org.
21. Zhang Q, Kandic I, Kutryk MJ. Dysregulation of angiogenesis-related micro-RNAs in endothelial progenitor cells from patients with coronary artery disease. Biochem Biophys Res Commun 2011;405:42-46.
22. 2+-calmodulin-dependent protein kinase II represses cardiac transcription of the L-type calcium channel alpha(1c)-subunit gene (cacna1c) by dream translocation. J Physiol 2011;589:2669-2686.
23. Higashikuni Y, Sainz J, Nakamura K, Takaoka M, Enomoto S, Iwata H, Tanaka K, Sahara M, Hirata Y, Nagai R, Sata M. The ATP-binding cassette transporter ABCG2 protects against pressure overload-induced cardiac hypertrophy and heart failure by promoting angiogenesis and antioxidant response. Arterioscler Thromb Vasc Biol 2012;32:654-661.
24. Novik KL, Spinelli JJ, Macarthur AC, Shumansky K, Sipahimalani P, Leach S, Lai A, Connors JM, Gascoyne RD, Gallagher RP, Brooks-Wilson AR. Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007;16:1098-1106. (Pubitemid 46984944)
25. Lu Y, Zhang Y, Wang N, Pan Z, Gao X, Zhang F, Shan H, Luo X, Bai Y, Sun L, Song W, Xu C, Wang Z, Yang B. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation 2010;122:2378-2387.
26. McManus DD, Beaulieu LM, Mick E, Tanriverdi K, Larson MG, Keaney JF, Benjamin EJ, Freedman JE. Relationship among circulating inflammatory proteins, platelet gene expression, and cardiovascular risk. Arterioscler Thromb Vasc Biol 2013;33:2666-2673.
27. de Boer HC, van Solingen C, Prins J, Duijs JM, Huisman MV, Rabelink TJ, van Zonneveld AJ. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J 2013;34:3451-3457.